Prognostic Value of Chemotherapy-Induced Amenorrhea in Breast Cancer: a Meta-Analysis

  • Zha, Quan-Bin (Department of Oncology, Jintan Hospital Affiliated to Jiangsu University) ;
  • Tang, Jin-Hai (Department of General Surgery, Jiangsu Cancer Hospital) ;
  • Li, Xiu-Juan (Department of General Surgery, Jiangsu Cancer Hospital) ;
  • Xia, Lei (Department of Pathology, Jiangsu Cancer Hospital) ;
  • Zhang, Zhe (Department of Pathology, Jiangsu Cancer Hospital) ;
  • Ren, Zhao-Jun (Department of Pathology, Jiangsu Cancer Hospital) ;
  • Xu, Xin-Yu (Department of Pathology, Jiangsu Cancer Hospital)
  • Published : 2015.09.02


Background: There is still a great deal of controversy with regard to the prognostic role of chemotherapy-induced amenorrhea (CIA) in breast cancer patients. To confirm whether CIA can serve as a useful factor in predicting clinical effects of systemic adjuvant chemotherapy, we performed this meta-analysis. Materials and Methods: Relevant studies were identified using PubMed, and Embase databases. Eligible study results were pooled and summary hazard ratios (HRs) with corresponding confidence intervals (CIs) were calculated. Subgroup analyses and an assessment of publication bias were also conducted. Results: A total of 8,333 patients from 11 published studies were identified through searching the databases. The pooled HRs for disease-free survival (DFS) suggested that CIA was associated with a significant reduction in the risk of recurrence, especially in patients with hormone receptor-positive lesions (overall HR=0.65, 95%CI 0.53-0.80, $I^2=41.3%$). When the five studies reporting the HR for overall survival (OS) were pooled (n=4193), a favorable trend was found (HR=0.69, 95%CI 0.52-0.91, $I^2=51.6%$). No publication bias was observed in this study. Conclusions: This meta-analysis suggests that CIA predicts a better outcome in premenopausal hormone receptor-positive breast cancer patients.


  1. Beex LV, Mackenzie MA, Raemaekers JM, et al (1988). Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour. Eur J Cancer Clin Oncol, 24, 719-21.
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  3. Bianco AR, Del Mastro L, Gallo C, et al (1991). Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer, 63, 799-803.
  4. Borde F, CMI, Fumoleau P, et al (2003). Role of chemo-induced amenorrhea in premenopausal, node-positive, operable breast cancer patients: 9-year follow-up results of French Adjuvant Study Group data base. Breast Cancer Res Treat, 82, 30.
  5. Brincker H, Rose C, Rank F, et al (1987). Evidence of a castrationmediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer. J Clin Oncol, 5, 1771-8.
  6. Budman DR, Berry DA, Cirrincione CT, et al (1998). Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer: The Cancer and Leukemia Group B. J Natl Cancer Inst, 90, 1205-11.
  7. Campora E, Pronzato P, Amoroso D, et al (1992). Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF. Anticancer Res, 12, 1555-8.
  8. Colleoni M, Gelber S, Goldhirsch A, et al (2006). Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol, 24, 1332-41.
  9. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet, 339, 71-85
  10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-717.
  11. Fisher B (1979). 1-phenylalanine mustard (L-Pam) in the management of premenopausal patients with primary breastcancer? Lack of association of disease-free survival with depression of ovarian function. Cancer, 44, 847-57.<847::AID-CNCR2820440309>3.0.CO;2-3
  12. Ganz PA, Land SR, Geyer CE Jr, et al (2011). Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol, 29, 1110-6.
  13. Goldhirsch A, Gelber RD, Castiglione M (1990). The magnitude of endocrine effects of adjuvant chemo-therapy for premenopausal breast cancer patients. Ann Oncol, 1, 183-8.
  14. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  15. Howell A, Rubens RD, Bush H, et al (1984). A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. Recent Results Cancer Res, 96, 74-89.
  16. Jakesz R, Hausmaninger H, Kubista E, et al (2002). Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol, 20, 4621-7.
  17. Jonat W, Kaufmann M, Sauerbrei W, et al (2002). Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with nodepositive breast cancer:The Zoladex Early Breast Cancer Res Association Study. J Clin Oncol, 20, 4628-35.
  18. Jung M , Shin HJ, Rha SY, et al. (2010). The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Followup. Ann Surg Oncol, 17, 3259-68.
  19. Leining MG, Gelber S, Rosenberg R, et al (2006). Menopausaltype symptoms in young breast cancer survivors. Ann Oncol, 17, 1777-82.
  20. Li XJ, Ren ZJ, Tang JH (2014). Lack of prognostic value of human epidermal growth factor- like receptor 2 status in inflammatory breast cancer (IBC): a meta-analysis. Asian Pac J Cancer Prev, 15, 9615-9
  21. Ludwig Breast Cancer Study Group (1985). A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res, 45, 4454-9.
  22. Mastro LD, Venturini M, Sertoli MR, et al (1997). Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Research and Treatment, 43, 183-90.
  23. Padmanabhan N, Rubens RD, Howell A (1986). Adjuvant chemotherapy in early breast cancer. Lancet, 2, 1333-4.
  24. Pagani O, O'Neill A, Castiglione M, et al (1998). Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer, 34, 632-40.
  25. Park H , Han H.S, Lee H, et al (2012). Resumption or persistence of menstruation after cytotoxic chemotherapy is a prognostic factor for poor disease-free survival in premenopausal patients with early breast cancer. Ann Oncol, 23, 2283-9.
  26. Parulekar WR, Day AG, Ottaway JA, et al (2005). Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study?NCIC CTG MA. 5. J Clin Oncol, 23, 6002-8.
  27. Richards MA, O'Reilly SM, Howell A, et al (1990). Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: An update of the Guy's/Manchester trial. J Clin Oncol, 8, 2032-9.
  28. Siegel R, Naishadham D, Jemal A (2015). Cancer statistics, 2015. CA Cancer J Clin, 65, 5-29.
  29. Swain SM, Jeong JH, Geyer Jr.CE, et al (2010). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med, 22, 2053-65.
  30. Swain SM, Land SR, Ritter MW, et al (2009). Amenorrhea in premenopausal women on the doxorubicin-andcyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat, 113, 315-20.
  31. Tierney JF, Stewart LA, Ghersi D, Burdett S, et al (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16.
  32. Tobias A (1999). Assessing the influence of a single study in the meta-anyalysis estimate. Stata Technical Bulletin, 8, 15-27.
  33. Tormey DC, Gray R, Abeloff MD, et al (1992). Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an eastern cooperative oncology group trial. J Clin Oncol, 10, 1848-56.
  34. Walshe JM, Denduluri N, Swain SM (2006). Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol, 24, 5769-79.
  35. Yazilitas D, Sendur MAN, Karaca H (2015). Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer. Asian Pac J Cancer Prev, 16, 1471-7.
  36. Yu KD, Shao ZM (2014). Survival benefit from response-guided approach: a direct effect of more effective cytotoxic regimens or an indirect effect of chemotherapy-induced amenorrhea? J Clin Oncol, 32, 1282-3.
  37. Zhao JL, Liu JQ, Chen K, et al (2014). What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Res Treat, 145, 113-28.